Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Fda Inspections
  6. /
  7. Baxter Oncology GmbH
FDA Inspection
•Baxter Oncology GmbH•September 26, 2025

Baxter Oncology GmbH – FDA Inspection, Sep 26, 2025

Record Details

This FDA Inspection record concerns Baxter Oncology GmbH, with an inspection on September 26, 2025, issued by the Office of Inspections and Investigations, covering human drugs.

Company
Baxter Oncology GmbH
Inspection Date
September 26, 2025
Product Type
Human Drugs
Office
Office of Inspections and Investigations
People
  • Justin A. Boyd (Investigator)
  • Karen A. Briggs (FDA Associated Person)
  • Vivin George (Investigator)
View Company Profile

ID · d2cc3497-33d6-41da-be71-fed681081e29

Inspection Facts

Official Action Indicated (OAI)

Significant objectionable conditions were found and regulatory or administrative action is recommended.

Inspection number
1283802
FDA center
Human Drugs
Project area
Drug Quality Assurance
Outcome
Form 483 issued, view the record

FDA Citations

12
  1. 21 CFR 211.56(a)Sanitation--buildings not clean, free of infestation
  2. 21 CFR 211.63Equipment Design, Size and Location
  3. 21 CFR 211.113(b)Validation lacking for sterile drug products
  4. 21 CFR 211.160(b)Scientifically sound laboratory controls
  5. 21 CFR 211.42(c)(10)(iv)Environmental Monitoring System
  6. 21 CFR 211.186(a)Written procedures followed
  7. 21 CFR 211.192Investigations of discrepancies, failures
  8. 21 CFR 211.22(a)Authority lacking to review records, investigate errors
  9. 21 CFR 211.113(b)Procedures for sterile drug products
  10. 21 CFR 211.100(a)Absence of Written Procedures

Showing 10 of 12 citations.

Full citation text and observation details available on the Dashboard.

Other FDA inspections of Baxter Oncology GmbH

11
DateClassificationOfficeProject area
August 27, 2024Not classifiedOffice of Inspections and Investigations
May 3, 2023NAICenter for Drug Evaluation and ResearchDrug Quality Assurance
January 29, 2020VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
September 3, 2019NAICenter for Drug Evaluation and ResearchDrug Quality Assurance
June 14, 2018VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
View all 11 other inspections on the company page
Other documents for Baxter Oncology GmbH
  • FDA Inspection 1249702 - 2024-08-27
  • FDA Inspection 1206312 - 2023-05-03
  • FDA Inspection 1161093 - 2020-01-29
  • FDA Inspection 1106642 - 2019-09-03
  • FDA Inspection 1056958 - 2018-06-14

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Baxter Oncology GmbH
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.